Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Alafenamide Sequential Therapy in Chronic Hepatitis B
NCT03471624Phase 4Completed
- Sponsor
- Stanford University
- Start
- May 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 4 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Stanford University. Started May 2018; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03471624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471624.